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Abstract
OBJECTIVE—The glycemic index (GI) of dietary carbohydrate is thought to affect glucose 
homeostasis. Recently, the OmniCarb Trial reported that a low GI diet did not improve insulin 
sensitivity. We conducted this ancillary study of the OmniCarb Trial to determine the effects of GI 
and carbohydrate content on glucose homeostasis and inflammation.
RESEARCH DESIGN AND METHODS—OmniCarb was a randomized crossover feeding 
study conducted in overweight or obese adults without diabetes (N=163). Participants were fed 
each of 4 diets for 5 weeks with 2-week washout periods. Weight was held constant. Diets were: 
high GI (GI≥65) with high carbohydrate (58% kcal), low GI (GI≤45) with low carbohydrate (40% 
kcal), low GI with high carbohydrate; and high GI with low carbohydrate. We measured glycated 
albumin (GA), fructosamine, and high sensitivity C-reactive protein (CRP) at baseline and 
following each dietary period. These biomarkers were compared within-person between diets.
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RESULTS—The study population was 52% female and 50% black. Mean age was 53 (SD, 11) 
years; mean BMI was 32 (SD, 6) kg/m2. Reducing GI had no effect on GA or fructosamine, but 
increased fasting glucose in the setting of a high carbohydrate diet (+2.2 mg/dl; P=0.02). Reducing 
carbohydrate content decreased GA in the setting of a high GI diet (−0.2%; P=0.03) and decreased 
fructosamine in the setting of a low GI diet (−4 μmol/L; P=0.003). Reducing carbohydrate while 
simultaneously increasing GI significantly reduced both GA (−0.2%; P=0.04) and fructosamine 
(−4 μmol/L; P=0.009). Neither reducing GI nor amount of carbohydrate affected insulin or CRP.
CONCLUSIONS—Reducing carbohydrate, regardless of high or low GI, decreased GA and 
fructosamine. This suggests that reducing carbohydrate content, rather than GI, is a better strategy 
for lowering glycemia in adults at risk for diabetes.
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INTRODUCTION
Randomized clinical trials examining the effects of dietary patterns on traditional 
cardiovascular disease risk factors have helped inform national dietary guidelines (1,2). 
Recently the OmniCarb Trial tested whether modifying the amount or type of carbohydrate 
could reduce cardiovascular risk factors (3). It was found that at high dietary carbohydrate 
content, reducing glycemic index (GI) decreased insulin sensitivity and increased LDL 
cholesterol, but did not affect HDL cholesterol, triglycerides, or blood pressure (3). In this 
trial, insulin sensitivity was determined by an oral glucose tolerance test, conducted in the 
morning after an overnight fast; glucose and insulin were measured at 7 time points. 
However, the oral glucose tolerance test does not represent the overall glycemic effects of 
dietary patterns that vary in amount and type of carbohydrate. Glycated albumin and 
fructosamine, markers of 2–3 week cumulative exposure to blood glucose, may be especially 
well-suited for evaluating the effects of dietary carbohydrates on glycemia in an 
intermediate-term trial setting. Both glycated albumin and fructosamine are formed by 
glycation reactions during which glucose binds with intravascular proteins, including 
albumin (4,5) and are associated with risk of diabetes (6,7) and cardiovascular disease events 
(8).
It has been hypothesized that the associations between GI and risk of diabetes and 
cardiovascular disease are mediated through low-grade inflammation (9,10). Observational 
studies have shown that C-reactive protein, a marker of inflammation, is associated with 
both diabetes (11) and cardiovascular disease (12). Further, several studies have described 
cross-sectional associations between GI and C-reactive protein (13–16); however, this has 
not been observed prospectively (17).
The objectives of this paper were (1) to determine the effects of diets that vary in 
carbohydrate type and amount on intermediate-term markers of glycemia in an overweight 
and obese population using glycated albumin and fructosamine, (2) to evaluate whether risk 
factors associated with diabetes modify the association between diet and intermediate-term 
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markers of glycemia, (3) to compare the cross-sectional association of these markers with 
traditional diabetes risk factors, and (4) to assess whether changes in GI or amount of dietary 
carbohydrate affect C-reactive protein. We hypothesize that reducing glycemic index and 
reducing content of carbohydrate will each lower intermediate-term glycemia measured by 
glycated albumin or fructosamine. Our secondary hypothesis is that lowering glycemic index 
or content of carbohydrate would lower inflammation measured by C-reactive protein.
Research Design and Methods
The Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart 
Disease and Diabetes Study (OmniCarb) was an investigator-initiated National Heart, Lung, 
and Blood Institute-sponsored study, whose rationale and main results have been published 
(3). OmniCarb was a randomized, controlled, crossover trial, comprising 4-dietary 
intervention periods. Participants each consumed 4 distinct diets in random order. The 4 
diets varied by GI (≥65 versus ≤45) and carbohydrate amount (40% vs. 58% kcal) as 
follows: high carbohydrate and high GI, high carbohydrate and low GI, low carbohydrate 
and high GI, or low carbohydrate and low GI. A detailed description of the diets is in Table 
1. GI is a measure of the amount that blood glucose increases after a standardized amount of 
carbohydrates (18). It is a relative scale based on the area under the glucose curve during a 
2-hour period after eating a standardized amount of a food item (18). For example, using 
white bread as a reference food, white rice and baked potatoes have a higher GI, while oat 
bran bread and long-grain rice have a lower GI (19). Currently, glucose content is the 
reference.
Participant Recruitment
Trial participants were adult men and women, residing in and around Boston, MA, and 
Baltimore, MD. Participants were aged 30 and older with systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) ranging from 120–159 and 80–99 mmHg, respectively. 
Persons with a prior diagnosis of diabetes or cardiovascular disease and persons taking 
medications for blood pressure, lipids, or diabetes were excluded from trial participation (3). 
Institutional Review Boards at Johns Hopkins University, Brigham & Women’s Hospital, 
and the Harvard School of Public Health approved the study protocol.
Controlled Feeding
Feeding by cohort began in August 2009 and was completed in September 2010. 
Participants were randomly assigned to 1 of 8 dietary sequences of the 4 diets and received 
100% of their meals from each study center (3). Each diet was designed to be healthful like 
the DASH diet (1) using commonly available foods and was reduced in saturated fat, 
cholesterol, and sodium, but rich in fruits, vegetables, fiber, potassium, and other minerals. 
Both fiber and sodium content was constant across diets. Because many low GI foods are 
high in fiber and many high GI foods are low in fiber, we established similar fiber contents 
across diets by including low-fiber, low-GI foods such as pasta and high-fiber high-GI foods 
such as instant oatmeal and bananas, and adding unprocessed wheat bran to 3 of the 
breakfasts and 2–3 dinners.
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Study participants underwent an 8-day run-in phase during which each of the 4 study diets 
was given for 2 days. Afterward, participants consumed each diet over a 5-week period 
followed by a 2-week washout, during which they ate a self-selected diet. Calorie targets 
were determined for each participant based on their body size, sex, and physical activity 
level. Calorie intake was adjusted throughout the trial to keep weight within 2% of 
participants’ baseline values. Participants were encouraged to maintain the same activity 
levels and alcohol consumption throughout the study. Attendance at meals was recorded. 
Participants were required to eat one principal meal on-site and were observed while eating. 
Participants were sent home with the remaining two meals. Every day, participants 
completed a diary in which they listed their consumption of protocol and non-protocol 
foods. Overall, adherence was high; all study foods with no non-study foods were consumed 
on 96% of person-days (3). Any alcohol consumption was reported on 11% of person-days.
Measurement of outcomes: fasting glucose, fasting insulin, glycated albumin, 
fructosamine, and high sensitivity C-reactive protein
Fasting laboratory specimens were collected at baseline prior to randomization and at the 
completion of each 5-week feeding period. The mean number of weeks between laboratory 
measurements in consecutive diet periods was 7.6 (SD, 2.0). Glucose and insulin were 
measured in serum after a brief storage period soon after specimen collection as part of the 
original trial protocol (3). Additional plasma specimens were stored at −70°C. Glycated 
albumin (Asahi Kasei Lucica GA-L; Asahi Kasei Pharma Corporation, Tokyo, Japan), 
fructosamine, and high sensitivity C-reactive protein were measured in year 2012 using 
stored plasma specimens with a Siemens Dimension Vista 1500 chemical analyzer (Siemens 
Healthcare Diagnostics, Glasgow, DE, Germany). Glycated albumin was assessed via an 
enzymatic method, involving oxidase and peroxidase reactions that yield a salt with a blue-
purple pigment, measured via spectroscopy. Fructosamine was measured with a colorimetric 
assay to detect the rate at which ketoamines reduce nitrotetrazolium-blue (NBT) to formazan 
in an alkaline solution. The rate of formation of formazan is directly proportional to the 
concentration of fructosamine. The observed inter-assay coefficients of variation for 
glycated albumin and fructosamine were 7.6% (glycated albumin, mean 13.7%) and 2.0% 
(fructosamine, mean 309 μmol/L), while manufacturer reported performance is <3% and 
2.9%, respectively. Glycated albumin was expressed as a percentage of total serum albumin 
according to the manufacturer’s instructions: [(glycated albumin concentration in g/dL/
serum albumin concentration in g/dL)* 100/1.14] + 2.9. In a general population without 
diabetes, glycated albumin ranges from 7.7 to 15.4%; while fructosamine ranges from 89 to 
267 μmol/L (8). High sensitivity C-reactive protein was also measured in stored plasma 
using an assay of polystyrene particles coated with monoclonal antibodies specific to C-
reactive protein (20). The C-reactive protein assay’s coefficient of variation was 2.3% (mean 
3.0 mg/L).
Other Covariate Measurements and Definitions
Body mass index (BMI) was calculated using baseline height and weight measurements and 
categorized as overweight (25–29.9 kg/m2) or obese (≥ 30 kg/m2). Waist circumference (cm) 
was measured at the level of the umbilicus. The homeostasis model assessment index 
(HOMA) was calculated as follows: HOMA = [(fasting serum insulin concentration in 
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μU/mL) × (fasting serum glucose concentration in mg/dL)]/405 (21). HOMA was further 
dichotomized based on the baseline median value of ≥ 1.48 units. Ultracentrifugation was 
used to prepare LDL for cholesterol measurements (3). HDL-cholesterol was measured by a 
precipitation method using dextran sulfate 50,000 MW and magnesium chloride (3). 
Cholesterol and triglycerides were measured by enzymatic assays. Triglycerides were 
dichotomized using the baseline median value of 83.8 mg/dL. Hypertensive status (yes or 
no) was determined by an average of 3 baseline blood pressure measurements for which 
mean systolic blood pressure was >140 mmHg or mean diastolic blood pressure was >90 
mmHg.
Statistics
The main outcomes examined in this study were plasma glycated albumin and plasma 
fructosamine. Serum fasting glucose and insulin were reported previously (3) but are 
included here as relevant outcomes to the research question. C-reactive protein was 
measured to examine the effects of the diets on inflammation. The primary comparison in 
this study was the end-of-period concentrations of the primary outcomes by diet. There were 
six pairs of dietary differences for each outcome: (i) high carbohydrate, high GI vs. high 
carbohydrate, low GI; (ii) low carbohydrate, high GI vs. low carbohydrate, low GI; (iii) high 
carbohydrate, high GI vs. low carbohydrate, high GI; (iv) high carbohydrate, low GI vs. low 
carbohydrate, low GI; (v) high carbohydrate, high GI vs. low carbohydrate, low GI; and (vi) 
high carbohydrate, low GI vs. low carbohydrate, high GI.
Although this 4-period crossover study could be analyzed as a factorial design, we 
considered that GI may have a stronger effect in a diet with high than low carbohydrate 
content and that carbohydrate amount may have a stronger effect when the GI is high rather 
than low. Therefore, a factorial analysis was considered inappropriate as described in the 
trial’s protocol (3).
In addition, using the high GI, high carbohydrate diet for comparison, we performed 
stratified analyses by covariates known a priori to be associated with insulin resistance, 
namely, race (non-Hispanic black versus white), baseline hypertensive status, baseline 
triglycerides, baseline BMI, baseline HOMA, baseline fasting glucose (<100 mg/dL, ≥100 
mg/dL), baseline glycated albumin (based on the population median ≤14.8%, >14.8%), and 
baseline fructosamine (based on the population median ≤234.5 μmol/L, >234.5 μmol/L). All 
of the above comparisons between strata were performed via generalized estimating 
equation (GEE) regression models, using a Huber and White robust variance estimator (22), 
which assumed an exchangeable working correlation matrix. P-values for each stratum were 
generated using interaction terms.
Moreover, in the baseline period, when participants were eating their usual self-selected 
diets, we evaluated the association between glycated albumin and fructosamine with BMI, 
waist circumference, HDLc, LDLc, triglycerides, serum glucose, serum insulin, and HOMA 
using Pearson’s coefficients and linear regression models adjusted for age, sex, and race.
All analyses were performed in Stata version 14.0 (Stata Corporation, College Station, TX, 
USA). Statistical significance was defined as P ≤ 0.05 without Bonferroni correction (23). 
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We did not correct the alpha level because the new outcomes, glycated albumin and 
fructosamine, measure the same metabolic process; fructosamine like glycated albumin is 
formed during the glycation reaction with blood proteins.
During the laboratory process, it was discovered that 95 of 749 (13%) samples were slightly 
hemolyzed and 17 (2%) were moderately hemolyzed based on visual inspection. Both slight 
and moderate hemolysis were associated with significant decreases in glycated albumin 
(−1.2 and −6.1%; P-values < 0.001) and significant increases in fructosamine (10.7 and 24.7 
μmol/L; P-values < 0.001). As a result, we excluded these samples from all glycated albumin 
and fructosamine comparisons. We further excluded participants who did not have a blood 
sample for glycated albumin or fructosamine in at least 2 visits (N = 3), the minimum 
number of data points necessary for a comparison. Both hemolysis and other missing data 
specimens were found to be evenly distributed between feeding periods and diets. A 
sensitivity analysis excluding hemolyzed samples from glucose and insulin comparisons had 
virtually no effect on our analysis (results not shown).
RESULTS
Baseline characteristics
Baseline characteristics of the randomized, study population are in Table 2. Overall the 
mean age was 52.6 ± 11.4 years; 52% of the participants were women and 50% were non-
Hispanic black race. Furthermore, 56% of the study population were obese and 26% had 
hypertension.
Comparison of glycemic markers between diets
Reducing GI had no effect on glycated albumin or fructosamine in the context of either high 
or low carbohydrate intake (Figure 1). Reducing GI increased fasting glucose in the context 
of a low carbohydrate diet (low GI/low carbohydrate vs. high GI/low carbohydrate: +2.2 
mg/dL, 95% CI: 0.4, 4.0; P = 0.02), but not significantly in the context of a high 
carbohydrate diet (+1.7 mg/dL, 95% CI: −0.5, 3.7; P = 0.12). Reducing GI had no effect on 
fasting insulin.
Reducing dietary carbohydrate in the setting of a high GI diet decreased glycated albumin 
(−0.2%, 95% CI: −0.4, −0.02; P = 0.03), while reducing dietary carbohydrate in the setting 
of a low GI diet significantly decreased fructosamine (−3.9 μmol/L, 95% CI: −6.4, −1.3; P = 
0.003). Reducing amount of dietary carbohydrate while simultaneously increasing GI, 
decreased both glycated albumin and fructosamine (glycated albumin −0.2%, 95% CI: −0.4, 
−0.01; P = 0.04; fructosamine −3.5 μmol/L, 95% CI: −6.2, −0.8; P = 0.01). The decreases in 
glycated albumin and fructosamine from reducing dietary carbohydrates were attenuated 
when GI was simultaneously decreased. Reducing dietary carbohydrates did not affect 
fasting glucose except when GI was reduced simultaneously. Reducing dietary 
carbohydrates had no effect on fasting insulin regardless of low GI, high GI, increase in GI, 
or decrease in GI.
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Stratified analyses and other sensitivity analyses
The diets’ effects on glycated albumin and fructosamine by strata of factors associated with 
diabetes are displayed in Supplement Tables S1 and S2. Ultimately, there was little if no 
evidence of interactions by race, hypertension status, baseline triglycerides, BMI, HOMA, 
baseline fasting glucose, baseline glycated albumin, or baseline fructosamine.
The baseline measures of glycated albumin and fructosamine were correlated (r = 0.58) 
(Supplement Table S2). Lower glycated albumin and fructosamine were associated with 
lower BMI and waist circumference.
There was no effect from change in either GI or amount of dietary carbohydrate on high 
sensitivity C-reactive protein (Supplement Figure S1).
CONCLUSIONS
In this trial of adults at risk for diabetes, we found that reducing GI increased fasting 
glucose, particularly in the setting of a low carbohydrate diet. However, these increases in 
fasting glucose had little influence on markers of 2–3 week glycemia, glycated albumin and 
fructosamine, likely because of the opposite direction of effects conferred by reducing 
postprandial glycemia from the reduced GI diet. In contrast, reducing the amount of dietary 
carbohydrate generally reduced glycated albumin and fructosamine, suggesting that reducing 
dietary carbohydrate may represent a more effective strategy than reducing GI for lowering 
glycemia in overweight or obese adults.
In this ancillary study to the OmniCarb trial, we present the effects of type and amount of 
carbohydrate on glycated albumin and fructosamine. Glycated albumin and fructosamine are 
intermediate-term markers of glycemia that are highly associated with hemoglobin A1c (24) 
and are elevated prior to the development of diabetes (6). They are formed by a 
nonenzymatic glycation reaction in which glucose forms a covalent bond with intravascular 
proteins, primarily albumin (4,5), and, as observed in this study, they are correlated with 
each other (r = 0.58). The half-life of these markers ranges between 17–21 days; thus 
glycated albumin and fructosamine represent an average exposure to glucose concentrations 
in the blood in the previous 2–3 weeks (4,5,25–27). There is growing evidence that these 
intermediate-term markers of glycemia are more meaningful indicators of risk for diabetes, 
cardiovascular disease, and mortality than single glucose measurements (7,8,24,28) by 
representing the aggregate effects of both fasting glucose and postprandial glucose 
excursions (29).
GI is a measure of carbohydrate “quality,” based on the rate of glucose released into 
circulation after consumption of a fixed amount of carbohydrates. It is typically determined 
by comparing the area of the glucose curve following the consumption of 50 grams of a 
carbohydrate food relative to a referent 50-gram food such as white bread or glucose (18). 
GI has been the target of nutrition policy advocates based on numerous observational studies 
(30), showing that lower GI is associated with lower risk of type 2 diabetes (31), 
cardiovascular disease (32,33), and mortality (34). Mechanistic explanations for these 
relationships have included the hypothesis that a high GI diet increases late postprandial 
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hepatic glucose, reflected in higher fasting glucose measures (35). In our study, we found the 
contrary to be true, that is, low GI diets increased fasting glucose. We suspect that the 
reduction in GI caused a compensatory increase in gluconeogenesis and a reduction in 
insulin sensitivity in order to stabilize fasting glucose levels, protecting against night-time 
and early morning hypoglycemia. This mitigated the expected increase in glycemia from 
high postprandial glucose excursions during the high GI diet. As a result, there was no effect 
on glycated albumin or fructosamine. This is consistent with a number of trials, which found 
no effect from GI on fructosamine or other glycation products like hemoglobin A1c in 
nondiabetic populations (36).
Like GI, the proportion of calories derived from carbohydrates has been associated with risk 
of diabetes and cardiovascular disease in observational studies (31,37,38) and clinical trials 
(39–41). Unlike GI, we found that reducing the amount of dietary carbohydrates was 
associated with reductions in either glycated albumin (high GI diets) or fructosamine (low 
GI diets). Interestingly, there were significant reductions in both glycated albumin and 
fructosamine when GI was increased while the amount of carbohydrates was decreased, but 
not when GI was decreased as amount of carbohydrates was decreased. This likely reflects 
the fact that decreasing GI increased fasting glucose, which would oppose the effect of 
reducing carbohydrates on glycated albumin and fructosamine. Overall, these results suggest 
that dietary carbohydrate is more important than GI as a dietary factor influencing aggregate 
glycemic exposure. Whether these differences in the effect of dietary carbohydrate on 
glycemia affect progression to diabetes or CVD should be a focus of subsequent research.
Prior studies have shown that a higher GI diet is associated with higher levels of C-reactive 
protein (13–16), a marker of inflammation associated with risk for diabetes or cardiovascular 
disease (11,12). This has led to the hypothesis that inflammation may mediate the 
association of GI with cardiovascular disease (9,10). In this ancillary study, we found no 
effect from either GI or amount of carbohydrates on C-reactive protein levels. This suggests 
that carbohydrates do not act via inflammation with regards to the pathogenesis of diabetes 
or cardiovascular disease.
This study has several limitations. The feeding periods were too brief for the observation of 
clinical events, making it necessary to examine surrogate markers as outcomes; however, we 
consider the feeding periods sufficient to determine effects on the surrogate outcomes. Based 
on our experience with prior feeding studies (1,2,42), effects of diet are observed soon after 
the initiation of feeding with the majority of effects taking place within the first two weeks 
(43). Thus, we are confident that even those with a short feeding period would still manifest 
an effect from GI if one existed. We reviewed the literature on duration for effects of GI, and 
if anything find a diminution of effects on risk factors with duration, especially beyond 6 
months (44). In a systematic review and meta-analysis that included 421 participants in 4 
trials with at least 6 months duration, reducing GI had no effect on hemoglobin A1C (mean 
difference −0.1%, P = 0.7) (45). Finally, 15% of the plasma specimens were hemolyzed and 
subsequently excluded from our analyses of glycated albumin and fructosamine, which 
reduced statistical power.
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With regards to strengths, our study was a randomized, controlled feeding study that 
employed a crossover design to assess dietary effects on glucose homeostasis. Diets were 
highly regulated and isocaloric with virtually no weight change over the course of the trial, 
reducing the impact of weight on our outcomes. Furthermore, we utilized non-traditional 
markers of glucose homeostasis that reflect intermediate-term glycemic exposure, permitting 
more accurate assessments of diet-induced changes in 2–3 week glucose homeostasis. 
Finally, our study population was quite diverse with 50% of participants being black, a 
population at risk for pre-diabetes and diabetes.
In conclusion, we found that a lower GI diet increases fasting glucose, while diets with a 
lower amount of dietary carbohydrates reduce glycated albumin and fructosamine, markers 
of 2–3 week glycemia. Together these findings suggest that a low carbohydrate diet most 
effectively lowers glycemia in adults at risk for diabetes. Additional research is needed to 
determine the long-term effects of these physiologic changes in glucose homeostasis on 
clinical outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated 
albumin (%), and (D) plasma fructosamine (μmol/L) measured at the end of each feeding 
period: between diet comparisons, mean and 95% confidence intervals. The feeding periods 
are grouped by glycemic index comparisons (low versus high glycemic index), carbohydrate 
proportion (low versus high proportion), and changes in both glycemic index and amount of 
carbohydrates, i.e. reductions in both or an increase in glycemic index while decreasing 
amount of carbohydrate. Hemolyzed samples comprising 15% of the total were removed 
from the glycated albumin and fructosamine comparisons.
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Table 2
Baseline characteristics of trial participants (N = 163), mean (SD) or No. (%)
Age, y 52.6 (11.4)
Women, % 85 (52)
Race, %
 Non-Hispanic White 66 (40)
 Non-Hispanic Black 82 (50)
 Hispanic 11 (7)
 Asian 4 (2)
Body mass index, kg/m2 32.3 (5.5)
Body mass index, %
 25–29.9 71 (44)
 ≥ 30 92 (56)
Waist circumference, cm 104.4 (13.5)
Homeostasis model assessment (HOMA), units 1.9 (1.6)
Triglycerides, mg/dL 104.6 (67.1)
HDL cholesterol, mg/dL 58.3 (16.0)
LDL cholesterol, mg/dL 153.0 (42.1)
Systolic blood pressure, mm Hg 132.0 (9.1)
Diastolic blood pressure, mm Hg 80.0 (7.5)
Baseline hypertensive status*, %
 Non-hypertensive 120 (74)
 Hypertensive 43 (26)
*
Defined as baseline SBP≥140 or DBP≥90 mmHg
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